X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.
| Revenue (Most Recent Fiscal Year) | $2.56M |
| Net Income (Most Recent Fiscal Year) | $-37.45M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.52 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.71 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 47.58% |
| Net Margin (Trailing 12 Months) | 46.54% |
| Return on Equity (Trailing 12 Months) | -181.56% |
| Return on Assets (Trailing 12 Months) | -54.36% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.58 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 3.30 |
| Inventory Turnover (Trailing 12 Months) | 2.40 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.90 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-21.32 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.14 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 5.79M |
| Free Float | 5.67M |
| Market Capitalization | $16.32M |
| Average Volume (Last 20 Days) | 0.31M |
| Beta (Past 60 Months) | 0.67 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.15% |
| Percentage Held By Institutions (Latest 13F Reports) | 72.03% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |